Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANA-DIA-FIB: Canagliflozin in T2D Patients With High Cardiovascular Risk
NCT05367063Phase 4Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of canagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Change in myocardial fibrosis at 26 weeks. Started Jan 2022; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05367063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367063.